Key facts
- Fore Biotherapeutics’s last known valuation is $198.2M (Apr 2025).
- It has raised $190.7M; the latest was Later Stage VC ($115.2M) in Apr 2025.
- Notable investors include OrbiMed, Wellington Management, Cormorant Asset Management, SR One Capital Management, Novartis Venture Fund — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Fore Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Fore Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fore Biotherapeutics
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and gnomically defined cancer patients. The company's clinical-stage drug development aids in recapitulating naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, enabling biopharma companies to receive support in identifying new target mutations and expanding subgroups of cancer patients to respond to existing therapies.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2011
- Employees
- 49
- Website
- fore.bio/
- Ownership
- Privately Held (backing)
Fore Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fore Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fore Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.